TWEAK and monocyte to HDL ratio as a predictor of metabolic syndrome in patients with polycystic ovary syndrome

Basit Öğe Kaydı
dc.contributor.authorDinçgez Çakmak, Burcu
dc.contributor.authorDündar, Betül
dc.contributor.authorKetenci Gençer, Fatma
dc.contributor.authorAydın Boyama, Burcu
dc.contributor.authorYıldız, Durkadın Elif
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:49:45Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:49:45Z
dc.date.issued2019
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Kadın Hastalıkları ve Doğum Ana Bilim Dalı
dc.descriptionWOS: 000459591100015
dc.descriptionPubMed ID: 30241442
dc.description.abstractWe aimed at analyzing serum TWEAK levels and monocyte/HDL ratio in polycystic ovary sazyndrome (PCOS) and their predictivity for metabolic syndrome (MS) in PCOS. We included 71 women with PCOS and 40 healthy controls without any cardiovascular risk factors in this cross-sectional study. Patient group was classified as MS positive (n = 34) and negative (n = 37). Study group had higher monocyte/HDL ratio and TWEAK levels (9.59 +/- 2.82 vs 8.2 +/- 2.46, p = .007 and 1085.54 +/- 780.95 vs 694.88 +/- 369.67 ng/ml, p = .009). Monocyte/HDL ratio and TWEAK levels were higher in MS positive group (10.47 +/- 2.81 vs 8.77 +/- 2.61, p = .01 and 1417.59 +/- 921.52 vs 780.41 +/- 455.67, p = .009). In multivariate regression analysis, monocyte/HDL ratio (>9.9, OR 3.42, 95%CI 1.41-5.78, p = .008) and TWEAK (>846.5 ng/ml, OR 5.49, 95%CI 3.14-7.59, p = .002) were found to be independent predictors of MS in study group. Discriminative value of monocyte/HDL ratio for MS in study group was evaluated by receiver operating curve. Area under curve for monocyte/HDL ratio was 0.669 with a sensitivity of 70.3% and specifity of 67.7%, cutoff value was>9.9. Receiver operating curve for TWEAK at>846.5 pg/ml threshold to diagnose MS in study group was performed and area under the curve was 0.769 with a sensitivity of 73% and specifity of 72%. TWEAK and monocyte/HDL ratio may be promising in predicting MS at early stages in PCOS to prevent future cardiovascular diseases by modifying life-style or giving pharmacotheraphy.
dc.identifier.citationAydın Boyama, B., Dündar, B., Ketenci Gençer, F., Dinçgez Çakmak, B. ve Yıldız, D. E. (2019). TWEAK and monocyte to HDL ratio as a predictor of metabolic syndrome in patients with polycystic ovary syndrome. Journal of Gynecological Endocrinology, 35(1), 66-71. https://dx.doi.org/10.1080/09513590.2018.1490401
dc.identifier.doi10.1080/09513590.2018.1490401
dc.identifier.endpage71
dc.identifier.issn0951-3590
dc.identifier.issn1473-0766
dc.identifier.issue1
dc.identifier.scopusqualityQ2
dc.identifier.startpage66
dc.identifier.urihttps://dx.doi.org/10.1080/09513590.2018.1490401
dc.identifier.urihttps://hdl.handle.net/20.500.12511/1747
dc.identifier.volume35
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofGynecological Endocrinologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectMonocyte to HDL Cholesterol Ratio
dc.subjectMetabolic Syndrome
dc.subjectPolycystic Ovary Syndrome
dc.subjectTWEAK
dc.titleTWEAK and monocyte to HDL ratio as a predictor of metabolic syndrome in patients with polycystic ovary syndrome
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Aydın Boyama, Burcu-2019.pdf
Boyut:
733.66 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu